Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic nonvalvular atrial fibrillation

Dariusz Kosior, Grzegorz Opolski, Adam Torbicki

Med Sci Monit 2001; 7(1): CR68-73 :: ID: 510905

Abstract

Background: Sequential use of antiarrhythmic drugs may improve prognosis in chronic atrial fibrillation (AF). We conducted a prospective study of the efficacy of sequential antiarrhythmic drug therapy in sinus rhythm (SR) maintenance after a successful electrocardioversion (CV) in pts with chronic AF.
Material/Methods: 58 pts (64.3&plusm;4.3 years old) with chronic AF underwent CV. After SR restoration (Group I) pts received one of the following antiarrhythmic drugs (Drug I): propafenone, sotalol or disopyramide. In case of arrhythmia recurrence, second CV was performed and pts received another drug from those mentioned above (Drug II). If treatment proved to be unsuccessful pts received amiodarone (Drug III) and third CV was attempted. After first unsuccessful CV (Group II) pts received a loading dose of amiodarone and another CV was attempted. In case of SR restoration amiodarone was administered continuously.
Results: After 12 months 81% pts were on SR; 85% pts received amiodarone continuously. After 1 year 6 (10%) pts presented with SR treated with Drug I (median 71 days); Drug II proved to be ineffective in all patients (median 27 days). 28 pts continued to receive amiodarone (no median).
Conclusions: sequential antiarrhythmic drug therapy improves arrhythmia prognosis in AF within a 12-month observation period. Amiodarone seems to be the most effective antiarrhythmic drug also in pts who required second CV proceeded by amiodarone treatment to restore SR.

Keywords: Atrial Fibrillation, antiarrhythmic treatment, electrocardioversion

Add Comment 0 Comments

Editorial

01 March 2025 : Editorial  

Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical Trials

Dinah V. Parums

DOI: 10.12659/MSM.948672

Med Sci Monit 2025; 31:e948672

0:00

In Press

Clinical Research  

Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.945964  

Clinical Research  

Inflammatory Biomarkers in Smokers: Implications for Ligamentum Flavum Hypertrophy

Med Sci Monit In Press; DOI: 10.12659/MSM.947508  

Clinical Research  

Balancing Image Quality and Iodine Intake: Insights from CT Spectral Imaging of the Portal Vein

Med Sci Monit In Press; DOI: 10.12659/MSM.947391  

Review article  

Regulatory Efforts and Health Implications of Energy Drink Consumption by Minors in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.947124  

Most Viewed Current Articles

17 Jan 2024 : Review article   7,160,485

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   702,385

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   27,806

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   22,071

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750